Erbitux Hearing Puts Focus On Pre-Approval Promotion, FDA Communication
Executive Summary
The House Energy & Commerce Committee is interested in looking further into FDA's authority to "rein in" pre-approval promotions
You may also be interested in...
FDA Emphasizing Written Communication With Sponsors On Pending NDAs
FDA will emphasize official written action letters in its internal policy on communication with sponsors drafted in response to the Congressional investigation of the Erbitux review, Acting Commissioner Crawford said Oct. 10
Erbitux Hearing May Feature FDA Reviewer Communication Policies
The House Energy & Commerce Committee's Oct. 10 follow-up hearing on the Erbitux (cetuximab) BLA may serve as a venue to discuss FDA's internal policy on communication between reviewers and sponsors over pending applications
Erbitux Hearing May Feature FDA Reviewer Communication Policies
The House Energy & Commerce Committee's Oct. 10 follow-up hearing on the Erbitux (cetuximab) BLA may serve as a venue to discuss FDA's internal policy on communication between reviewers and sponsors over pending applications